Second diabetes drug added to long list of shortages
Associate Professor Neale Cohen says there is a lack of good alternatives to once-weekly dulaglutide and semaglutide
A leading endocrinologist says patients with type 2 diabetes may have to revert to older treatments as a global shortage of dulaglutide begins to bite following a sharp rise in demand.
Last week, the TGA warned there would not be enough of the GLP-1 receptor agonist to fill all scripts until at least early 2023 and urged affected patients to be reassessed by a doctor as soon as possible.
